Literature DB >> 8221205

Recombinant antibody technology: its advent and advances.

N Hozumi1, J S Sandhu.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8221205     DOI： 10.3109/07357909309046945

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  3 in total

1.  Derivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein Scaffold.

Authors:  Anna V Lomonosova; Andrei B Ulitin; Alexei S Kazakov; Tajib A Mirzabekov; Eugene A Permyakov; Sergei E Permyakov
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

Review 2.  Oral delivery of antibodies. Future pharmacokinetic trends.

Authors:  R M Reilly; R Domingo; J Sandhu
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein Scaffold.

Authors:  Anna V Lomonosova; Elena V Ovchinnikova; Alexei S Kazakov; Alexander I Denesyuk; Alexander D Sofin; Roman V Mikhailov; Andrei B Ulitin; Tajib A Mirzabekov; Eugene A Permyakov; Sergei E Permyakov
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.